Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVKD Cadrenal Therapeutics	$13.13 -4.2%	$15.26	$5.70 ▼ $22.90	$27.26M	1.09	40,951 shs	15,015 shs
DARE Dare Bioscience	$2.91 -2.2%	$2.96	$2.67 ▼ $5.76	$26.82M	1.2	36,453 shs	20,707 shs
OMGA Omega Therapeutics	$0.13 -21.8%	$0.12	$0.10 ▼ $2.63	$6.92M	1.65	3.37 million shs	4.81 million shs
SXTC China SXT Pharmaceuticals	$1.86 +7.5%	$1.83	$0.95 ▼ $11.92	$28.97M	1.11	1.19 million shs	110,907 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVKD Cadrenal Therapeutics	-4.16%	-12.47%	-15.29%	-32.74%	+1,312,999,900.00%
DARE Dare Bioscience	-2.19%	-8.93%	+0.52%	-1.86%	-44.34%
OMGA Omega Therapeutics	0.00%	0.00%	0.00%	0.00%	-93.28%
SXTC China SXT Pharmaceuticals	+7.51%	-11.85%	+55.00%	-30.34%	-78.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVKD Cadrenal Therapeutics	3.255 of 5 stars	3.5	5.0	2.6	1.7	0.6
DARE Daré Bioscience	1.4121 of 5 stars	3.3	3.0	1.6	0.0	0.0
OMGA Omega Therapeutics	2.1456 of 5 stars	3.4	0.0	1.1	1.7	1.3
SXTC China SXT Pharmaceuticals	0.4305 of 5 stars	0.0	3.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	143.72% Upside
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	313.08% Upside
OMGA Omega Therapeutics	2.80	Moderate Buy	$8.50	6,700.00% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMGA, SXTC, CVKD, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	CVKD Cadrenal Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/1/2025	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$4.17 per share	N/A
DARE Dare Bioscience	$10K	2,570.93	N/A	N/A	($0.69) per share	-4.21
OMGA Omega Therapeutics	$8.10M	0.85	N/A	N/A	$1.05 per share	0.12
SXTC China SXT Pharmaceuticals	$1.93M	15.26	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVKD Cadrenal Therapeutics	-$10.65M	-$9.26	N/A	N/A	N/A	N/A	-244.94%	-181.94%	8/6/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-8.14%	8/11/2025 (Estimated)
OMGA Omega Therapeutics	-$97.43M	-$1.33	N/A	N/A	N/A	-902.93%	-213.13%	-41.24%	6/20/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OMGA, SXTC, CVKD, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/8/2025	Q1 2025	CVKD Cadrenal Therapeutics	-$1.64	-$2.09	-$0.45	-$2.09	N/A	N/A
3/31/2025	Q4 2024	DARE Dare Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
OMGA Omega Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVKD Cadrenal Therapeutics	N/A	3.69	3.69
DARE Daré Bioscience	N/A	1.14	1.14
OMGA Omega Therapeutics	1.00	1.61	1.61
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVKD Cadrenal Therapeutics	7.92%
DARE Dare Bioscience	6.70%
OMGA Omega Therapeutics	97.47%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
CVKD Cadrenal Therapeutics	48.62%
DARE Dare Bioscience	4.00%
OMGA Omega Therapeutics	8.50%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVKD Cadrenal Therapeutics	4	1.97 million	1.01 million	Not Optionable
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
OMGA Omega Therapeutics	120	55.37 million	50.66 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable

OMGA, SXTC, CVKD, and DARE Headlines

Recent News About These Companies

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16 at 12:26 PM | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMGA, SXTC, CVKD, and DARE Company Descriptions

Cadrenal Therapeutics NASDAQ:CVKD

$13.13 -0.57 (-4.16%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$14.00 +0.87 (+6.63%)

As of 06/17/2025 07:35 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Dare Bioscience NASDAQ:DARE

$2.90 -0.07 (-2.19%)

Closing price 06/17/2025 03:57 PM Eastern

Extended Trading

$2.88 -0.02 (-0.86%)

As of 06/17/2025 04:04 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)

Closing price 02/24/2025

Extended Trading

$0.12 0.00 (0.00%)

As of 02/24/2025 07:59 PM Eastern

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.86 +0.13 (+7.51%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$1.84 -0.02 (-0.81%)

As of 04:38 AM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time